TY - JOUR
T1 - Oxidopamine and oxidative stress
T2 - Recent advances in experimental physiology and pharmacology
AU - Pantic, Igor
AU - Cumic, Jelena
AU - Skodric, Sanja Radojevic
AU - Dugalic, Stefan
AU - Brodski, Claude
N1 - Publisher Copyright: © 2021 Elsevier B.V.
PY - 2021/2/25
Y1 - 2021/2/25
N2 - Oxidopamine (6-hydroxydopamine, 6-OHDA) is a toxin commonly used for the creation of experimental animal models of Parkinson's disease, attention-deficit hyperactivity disorder, and Lesch–Nyhan syndrome. Its exact mechanism of action is not completely understood, although there are many indications that it is related to the generation of reactive oxygen species (ROS), primarily in dopaminergic neurons. In certain experimental conditions, oxidopamine may also cause programmed cell death via various signaling pathways. Oxidopamine may also have a significant impact on chromatin structure and nuclear structural organization in some cells. Today, many researchers use oxidopamine–associated oxidative damage to evaluate different antioxidant-based pharmacologically active compounds as drug candidates for various neurological and non-neurological diseases. Additional research is needed to clarify the exact biochemical pathways associated with oxidopamine toxicity, related ROS generation and apoptosis. In this short review, we focus on the recent research in experimental physiology and pharmacology, related to the cellular and animal experimental models of oxidopamine - mediated toxicity.
AB - Oxidopamine (6-hydroxydopamine, 6-OHDA) is a toxin commonly used for the creation of experimental animal models of Parkinson's disease, attention-deficit hyperactivity disorder, and Lesch–Nyhan syndrome. Its exact mechanism of action is not completely understood, although there are many indications that it is related to the generation of reactive oxygen species (ROS), primarily in dopaminergic neurons. In certain experimental conditions, oxidopamine may also cause programmed cell death via various signaling pathways. Oxidopamine may also have a significant impact on chromatin structure and nuclear structural organization in some cells. Today, many researchers use oxidopamine–associated oxidative damage to evaluate different antioxidant-based pharmacologically active compounds as drug candidates for various neurological and non-neurological diseases. Additional research is needed to clarify the exact biochemical pathways associated with oxidopamine toxicity, related ROS generation and apoptosis. In this short review, we focus on the recent research in experimental physiology and pharmacology, related to the cellular and animal experimental models of oxidopamine - mediated toxicity.
KW - 6-hydroxydopamine
KW - Apoptosis
KW - Reactive oxygen species
KW - Toxicology
UR - http://www.scopus.com/inward/record.url?scp=85100211507&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.cbi.2021.109380
DO - https://doi.org/10.1016/j.cbi.2021.109380
M3 - Review article
C2 - 33450287
SN - 0009-2797
VL - 336
JO - Chemico-Biological Interactions
JF - Chemico-Biological Interactions
M1 - 109380
ER -